The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.

Malnutrition is a frequent comorbidity in head and neck cancer patients and has been shown to impair immunotherapy response in other cancer types. The geriatric nutritional risk index (GNRI) assesses malnutrition using the patient's ideal weight, actual weight, and serum albumin. The aim of this study was to evaluate the prognostic relevance of malnutrition as determined by the GNRI for the response to immunotherapy in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). A total of 162 patients with R/M HNSCC who received immune checkpoint inhibitors were included. The associations between the GNRI and progression-free survival (PFS), overall survival (OS), and the disease control rate (DCR) were computed. Univariable analysis showed worse PFS for GNRI ≤ 98 ( p < 0.001), ECOG performance status (PS) ≥ 2 ( p = 0.012), and enteral ( p = 0.009) and parenteral ( p = 0.015) nutritional supplementation, and worse OS for GNRI < 92 ( p < 0.001), ECOG PS ≥ 2 ( p < 0.001), and enteral ( p = 0.008) and parenteral ( p = 0.023) nutritional supplementation. In our multivariable model, GNRI ≤ 98 ( p = 0.012) and ECOG PS ≥ 2 ( p = 0.025) were independent prognostic factors for PFS. For OS, GNRI < 92 ( p < 0.001) and ECOG PS ≥ 2 ( p < 0.001) were independent prognostic factors. A GNRI ≤ 98 was significantly associated with a lower DCR compared to a GNRI > 98 ( p = 0.001). In conclusion, our findings suggest that the GNRI may be an effective predictor for response to immunotherapy in R/M HNSCC.